Zoledronic acid

Generic Name
Zoledronic acid
Brand Names
Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
Drug Type
Small Molecule
Chemical Formula
C5H10N2O7P2
CAS Number
118072-93-8
Unique Ingredient Identifier
70HZ18PH24
Background

Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...

Indication

Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...

Associated Conditions
Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
Associated Therapies
Bone Mineral Density
Clinical Trials
Related News

Bone Loss Treatment From Adjuvant Zoledronate Efficacy

Not Applicable
Terminated
Conditions
Breast Neoplasms
Bone Loss
Interventions
Drug: Zoledronate
First Posted Date
2012-06-20
Last Posted Date
2021-06-22
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
200
Registration Number
NCT01623908
Locations
🇨🇳

Guangzhou First Municipal People's Hospital, Guangzhou, Guangdong, China

🇨🇳

Shenzhen Second Municipal People's Hospital, Shenzhen, Guangdong, China

🇨🇳

Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

and more 7 locations

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass

Not Applicable
Completed
Conditions
Postmenopausal Osteoporosis
Interventions
Drug: Denosumab
Drug: Zoledronic acid
First Posted Date
2012-04-06
Last Posted Date
2013-01-17
Lead Sponsor
Aristotle University Of Thessaloniki
Target Recruit Count
91
Registration Number
NCT01572545
Locations
🇬🇷

251 Hellenic Air Force Hospital, Athens, Attikis, Greece

🇬🇷

424 General Military Hospital, Thessaloniki, Greece

🇬🇷

Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece

FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)

Phase 2
Terminated
Conditions
Osteoporosis
Interventions
Other: FES-Rowing
Drug: Zoledronic acid
First Posted Date
2011-08-31
Last Posted Date
2016-04-11
Lead Sponsor
Antonio Lazzari
Target Recruit Count
70
Registration Number
NCT01426555
Locations
🇺🇸

Boston VAMC, Boston, Massachusetts, United States

🇺🇸

Spaulding Rehab. Hospital, Charlestown, Massachusetts, United States

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

First Posted Date
2011-08-04
Last Posted Date
2020-05-08
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
9
Registration Number
NCT01409811
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma

Phase 1
Terminated
Conditions
Neuroblastoma
Interventions
Drug: Zoledronic Acid
Biological: Aldesleukin
First Posted Date
2011-07-28
Last Posted Date
2014-12-02
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
4
Registration Number
NCT01404702
Locations
🇺🇸

University of Alabama at Birmingham-Children's of Alabama, Birmingham, Alabama, United States

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

First Posted Date
2011-04-29
Last Posted Date
2022-11-08
Lead Sponsor
Amgen
Target Recruit Count
1718
Registration Number
NCT01345019
Locations
🇬🇧

Research Site, Oxford, United Kingdom

Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Patients With Metastatic Breast Cancer: Duration of Effect

First Posted Date
2011-04-29
Last Posted Date
2015-06-23
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
21
Registration Number
NCT01344967
Locations
🇨🇦

St. Michael's Hospital, Toronto, Ontario, Canada

THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)

Phase 2
Completed
Conditions
Multiple Myeloma
First Posted Date
2011-04-25
Last Posted Date
2011-04-25
Lead Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Target Recruit Count
378
Registration Number
NCT01341262

The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion

First Posted Date
2011-03-08
Last Posted Date
2011-03-08
Lead Sponsor
Fudan University
Target Recruit Count
50
Registration Number
NCT01310465
Locations
🇨🇳

Zhongshan hospital of Fudan university, Shanghai, Shanghai, China

Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

Phase 4
Completed
Conditions
Osteoporosis
Interventions
Other: Placebo
Drug: Zoledronic acid
First Posted Date
2010-12-28
Last Posted Date
2018-12-19
Lead Sponsor
Spokane Joint Replacement Center
Target Recruit Count
51
Registration Number
NCT01267279
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy